Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
Stocks · News reference
Myriad Genetics Announces New Data from MONSTAR-SCREEN-3 Study
Myriad Genetics released new data from its MONSTAR-SCREEN-3 study demonstrating the potential of its Precise MRD platform for detecting molecular residual disease in colorectal and pancreatic cancers.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Rises Over 100 Points; 3M Earnings Top Views
U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.